

Hybrid Coronary Revascularization for Multivessel Coronary Artery Disease: Strategies and Outcomes

Emmanuel Moss^{1*}, John D Puskas^{1,2} and Michael E Halkos³

¹Associate, Cardiothoracic Surgery, Emory University School of Medicine, USA

²Chief of Cardiac Surgery, Emory University Hospital Midtown, USA

³Division of Cardiothoracic Surgery, Emory University School of Medicine, USA

Abstract

Surgical and percutaneous treatments of coronary artery disease (CAD) have evolved in parallel over the last several decades. Both modalities now offer safe and effective relief from severe CAD, each with unique advantages and disadvantages. Hybrid coronary revascularization (HCR) provides a minimally invasive strategy that exploits the strengths of both traditional coronary artery bypass surgery (CABG) and percutaneous coronary intervention (PCI). HCR entails non-sternotomy left internal mammary artery (LIMA) harvest and grafting to the left anterior descending (LAD) artery, combined with percutaneous coronary intervention (PCI) to non-LAD vessels. The result is a complete revascularization, including the survival benefit of a LIMA-LAD graft, while avoiding the morbidity and convalescence associated with a sternotomy. This review will describe the methods of sternal sparing LIMA-LAD grafting in practice today and explore the various strategies and current evidence for HCR.

Keywords: Hybrid coronary revascularization; Robotic-assisted CABG; Minimally invasive cardiac surgery

Introduction

Coronary artery bypass grafting (CABG) and percutaneous coronary interventions (PCI) have evolved over the last several decades to become two of the world's most commonly performed, and most scrutinized, procedures. When combined with medical therapy, both CABG and PCI have demonstrated effectiveness in improving symptoms related to obstructive coronary artery disease [1-3]. In addition, CABG has shown a long-term survival benefit, which has been attributed primarily to the practice of bypassing the left anterior descending artery (LAD) using the left internal mammary artery (LIMA) [4]. While LIMA patency is excellent in the long-term, patency rates of saphenous vein grafts to non-LAD territories at 10 and 20 years have been suboptimal, ranging from 50-70% and 30%, respectively [5,6]. PCI has evolved from early simple angioplasty to the stent era, which has made the procedure safer and more reproducible. The incidence of repeat intervention has decreased significantly, although it remains higher with PCI than with CABG [7]. Fueled by the mediocre outcomes with saphenous vein grafts and decreased restenosis rates with drug eluting stents (DES), hybrid coronary revascularization (HCR) had attracted significant interest in recent years from both surgeons and cardiologists because it combines the advantages of each revascularization modality [8,9]. Asternal sparing surgical revascularization of the LAD using the LIMA is paired with PCI of non-LAD vessels, providing a minimally invasive approach using a conduit that has proven effective in improving long-term survival and a PCI strategy that will improve symptoms related to coronary artery disease (CAD). If both LAD and non-LAD territories are suitable for each respective procedure, we believe patients can derive significant benefit from this combined approach.

This review describes the various approaches for non-sternotomy LIMA harvesting and anastomosis, as well as the different HCR strategies. The available literature addressing outcomes in HCR will be reviewed.

Non-sternotomy LIMA-LAD Bypass

MIDCAB

Minimally invasive direct coronary artery bypass was first reported

in the 1990s and refers to the combination of LIMA takedown and LIMA-LAD anastomosis through a small anterior minithoracotomy [10,11]. This is accomplished via the 4th or 5th intercostal space and requires a specialized chest wall retractor and disarticulation or removal of costal cartilage. The advantage of MIDCAB, in comparison with other minimally invasive techniques, is that it does not require any specialized endoscopic or robotic training to accomplish LIMA harvest. On the other hand, extensive chest wall retraction is required and controlling postoperative pain can be difficult [12,13]. While MIDCAB has been demonstrated to be safe compared to conventional CABG, potentially incomplete LIMA harvest and the necessity for significant chest wall traction limit the potential benefits [14]. As a result, it is a far less attractive option than non-sternotomy CABG using thoracoscopic or robotic techniques, despite the necessity for additional equipment and expertise when using these techniques.

EndoACAB

Endoscopic atraumatic coronary artery bypass (EndoACAB) is defined as thoracoscopic LIMA harvest with a LIMA-LAD anastomosis accomplished through a minithoracotomy. Although this method requires single lung ventilation and CO₂ insufflation of the chest, it has several advantages over traditional MIDCAB. Firstly, harvest can be accomplished without significant upward retraction on the chest wall, theoretically decreasing postoperative pain and avoiding costal disarticulation. Access is obtained via three endoscopic ports placed in approximately the 3rd, 5th, and 7th intercostal spaces. Secondly,

*Corresponding author: Emmanuel Moss, Associate, Cardiothoracic Surgery, 201 Dowman Drive. Atlanta, Georgia 30322, USA, Tel: (404)904-6111; E-mail: emmanuel.moss@emory.edu

Received September 11, 2013; Accepted October 05, 2013; Published October 07, 2013

Citation: Moss E, Puskas JD, Halkos ME (2013) Hybrid Coronary Revascularization for Multivessel Coronary Artery Disease: Strategies and Outcomes. J Clin Exp Cardiol S7: 006. doi: [10.4172/2155-9880.S7-006](https://doi.org/10.4172/2155-9880.S7-006)

Copyright: © 2013 Moss E, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

visualization is much improved compared to traditional MIDCAB, and the LIMA can routinely be harvested along its entire length, mimicking what is typically accomplished via median sternotomy. Both pericardiotomy and target vessel localization can be performed endoscopically, thus limiting the size of the thoracotomy and the degree of requisite retraction. Following LIMA harvest, pericardiotomy, and identification of the LAD, a small 4-5cm anterior minithoracotomy is performed over the LAD. A rib spreader, or preferably a non-rib-spreading soft tissue retractor, is used to provide adequate visualization for placement of the stabilizer and completion of the hand-sewn anastomosis. The primary disadvantage of this technique, and the likely reason it has not developed widespread use, is the technical expertise and steep learning curve associated with thoracoscopic harvest.

Robotic-assisted CAB

Robotic-assisted CAB consists of a LIMA harvest performed through three endoscopic ports placed similarly to the thoracoscopic approach and a minithoracotomy through which a handsewn LIMA-LAD anastomosis is performed. Pericardiotomy and target vessel localization are also performed prior to thoracotomy, providing the same advantages as the thoracoscopic approach, but visualization is markedly improved and the learning curve is significantly shorter. In addition, robotic assistance allows the surgeon to perform all of the above-mentioned steps with greater precision and speed compared to the thoracoscopic approach. As with thoracoscopic MIDCAB, the patient benefits from minimal chest wall trauma and a handsewn anastomosis.

Robotic TECAB

Some surgeons have successfully taken minimally invasive coronary revascularization a step further in performing robot assisted totally endoscopic coronary artery bypass (Robotic TECAB). In its early stages, this procedure was performed on the arrested heart, with intra-aortic balloon occlusion. LIMA-LAD anastomosis is performed using either prolene or anastomotic assistance devices. Although the minithoracotomy is avoided, this approach carries with it the deleterious inflammatory response of cardiopulmonary bypass (CPB), theoretically negating any advantage over the robotic MIDCAB approach. The beating-heart TECAB technique that was later developed successfully avoids both the use of CPB and the necessity for a minithoracotomy. While short-term results have been good, the significant technical expertise required to safely perform this procedure combined with the minimal perceived advantage over robotic MIDCAB, has limited the widespread adoption of this technique. Achayra et al. draw a similar conclusion while concisely summarizing recent TECAB results [15].

Although our institution has previously published excellent minimally invasive CABG results with thoracoscopic MIDCAB, we have evolved to perform the robotic-assisted CAB technique exclusively. Considering the merits of each of the above techniques, we believe that robotic-assisted CAB is, at this time, the ideal minimally invasive revascularization technique, providing the best blend between practicality, "teachability", patient benefit, and operating room efficiency [16,17].

Hybrid Coronary Revascularization Strategies

In addition to the variety of operative techniques, there exist three strategies for timing of the hybrid revascularization, each with their own inherent advantages and shortcomings: 1) CABG followed by PCI, 2) PCI followed by CABG, or 3). Simultaneous CABG + PCI in a hybrid suite.

CABG followed by PCI

This approach entails initially performing minimally invasive CABG, followed days to weeks later by PCI of non-LAD territories. This can be done during the index hospitalization or at a later date, depending on the clinical scenario. The ideal timing of completion PCI has not been established and should be decided by taking into account the severity of the residual lesions and the overall clinical status of the patient following surgery. While this approach has several benefits, its primary advantage is that it permits CABG to be performed without the use of powerful antiplatelet agents (eg. Clopidogrel), which are necessary if PCI is performed preoperatively or as a combined procedure. Concurrent use of these medications may increase the risk of perioperative bleeding and the need for blood transfusions. Conversely, if PCI is performed before or concomitantly with the CABG procedure, delayed administration or temporary discontinuation of an antiplatelet agent would expose the patient to an increased risk of acute stent thrombosis. A second benefit of a "CABG first" approach is that patency of the LIMA-LAD graft can be verified angiographically at the time of stenting. Finally, this approach permits potentially high risk PCI to be performed for left main or diagonal branch bifurcation lesions with the protection of a LIMA-LAD graft. Patient selection is important and one must consider how the patient will tolerate LAD occlusion in the presence of significant untreated coronary disease. One must also be relatively certain that PCI of the non-LAD targets can be safely accomplished, to avoid the unfortunate situation of performing a sternotomy to rescue a failed PCI. The majority of our cases at Emory have been a "CABG first" approach, unless the culprit lesion involves a non-LAD artery. As mentioned above, this allows surgical intervention to be performed without increased bleeding risks due to antiplatelet therapy and avoids logistic issues of coordinating the surgical and cardiology teams to perform simultaneous revascularization.

PCI followed by CABG

Performing PCI prior to minimally invasive CABG has several potential benefits as well. Firstly, if PCI fails or gives suboptimal results, traditional CABG remains available as an excellent fallback option. Secondly, addressing non-LAD lesions prior to surgery may facilitate minimally invasive CABG by minimizing the potential for ischemia during LAD occlusion. This is particularly true in the setting of critical non-LAD disease. Finally, in patients presenting with an acute myocardial infarction, non-LAD culprit lesions can be stented and minimally LIMA-LAD grafting can be performed once the patient has recovered. Options for anticoagulation management are dependent on the type of stent used (BMS vs. DES), the clinical scenario, and surgeon experience. For example, if a BMS is used in the context of an acute MI, it may be reasonable to wait 1 month and temporarily discontinue clopidogrel therapy in order to perform minimally invasive LAD grafting. On the other hand, in the setting of a recent DES and severe LAD disease, it may be appropriate to perform minimally invasive CABG on clopidogrel, despite the increased risk of perioperative bleeding. As our experience has evolved, we have become more comfortable operating on patients without discontinuing clopidogrel therapy; however, the risks and benefits must be clearly explained to the patient.

Simultaneous CABG and PCI

A growing number of hospitals now have hybrid suites, which can be used to perform minimally invasive CABG followed immediately by PCI as a single procedure. This approach is attractive from both a

patient convenience and economic vantage point. Questions remain unanswered as to whether this is the ideal approach for hybrid revascularization. The most evident advantage of this approach is the ability to verify patency of the LIMA-LAD graft intraoperatively, even before chest closure. Additionally, as with the CABG-first technique, it permits safe performance of otherwise high-risk PCI, such as left main or other complex stenting. Finally, this approach is often preferred by patients, decreasing anxiety related to multiple procedures by allowing a complete revascularization under a single anesthesia sitting. Disadvantages include prolonged operating room time and difficulty coordinating operative and cardiac catheterization teams. In addition to these administrative challenges, bleeding concerns related to incomplete heparin reversal and intraoperative full antiplatelet therapies have limited the widespread application of this approach.

At the present time, no data exists clearly favoring any one of these three approaches [18]. The advantages and disadvantages of each of these three HCR strategies must be considered when selecting a treatment plan for each individual patient based on anatomical and clinical criteria.

Patient selection

As with most minimally invasive procedures, patient selection is critical. In the case of HCR, the surgeon must consider whether the patient is a suitable candidate for both PCI of non-LAD territories and minimally invasive CABG. As a prerequisite, surgical candidates should be clinically stable with no uncontrolled chest pain and have favorable body habitus and coronary anatomy. Ideal candidates are non-obese patient with large thoracic cavities and non-intramycardial LADs of large caliber.

We have seen two typical referral patterns for HCR patients. The first, and more suitable early in a surgeon's experience, is a healthy patient who recognizes the durability of CABG but wishes to avoid a sternotomy. The second group of patients would be at high risk for traditional sternotomy but present LAD disease that is not amenable to PCI or medical therapy. Contraindications to minimally invasive CABG include untreated left subclavian stenosis, morbid obesity, dense adhesions in the left chest (e.g. from previous surgery or infection), and severe lung disease. We strictly adhered to these principles early in our experience, however, more recently we have had success treating a carefully selected group of patients with poor pulmonary function or increased body mass index.

Results of Non-sternotomy CABG and HCR

Excellent results have been reported for all 4 minimally invasive techniques CABG. We have previously reported favorable results in a propensity-matched group of 597 patients undergoing non-sternotomy vs. sternotomy CABG [17]. 30-day mortality and adverse events, as well as midterm results, were similar. In a series of 100 consecutive MIDCABs, Mack et al reported an intraoperative graft patency of 99%, and no stenosis greater than 50% in 91% of patients [19]. Similar results were reported in a larger series of patients undergoing minimally invasive CABG, with 95.6% patency on routine predischarge angiograms in 709 patients [20]. Early and midterm clinical outcomes for MIDCAB have also been favorable; comparisons to median sternotomy showed equivalent outcomes, and comparisons with PCI have consistently shown a decreased rate of target vessel revascularization with no difference in other major cardiac events [14,21-25]. A meta-analysis of randomized trials comparing MIDCAB to PCI, which included a total of 711 patients, echoed these results [26].

Our institution has reported on early safety and feasibility, as well as midterm results, of EndoACAB [27]. In a series of 607 patients, Vassiliades et al reported a 1.0% 30-day mortality rate. Graft patency was 98.5% at a mean of 18.4 months postoperatively and 5-year event-free survival was 92%. It is worth reiterating however those, due to the technical challenges related to this procedure, other institutions have had difficulty reproducing these results.

In the last several years, robotic-assisted CAB has been gaining popularity due to the advantages detailed above and several small series have reported good early outcomes. Our group recently published our series of 271 consecutive robotic-assisted CAB procedures consisting of robotic LIMA harvest with LIMA-LAD anastomosis through a 3-4cm anterior minithoracotomy [28]. Neshet et al. reported on a series of 146 consecutive robotic-assisted CAB patients with no in-hospital deaths and 96.3% patency rate in 64 routine angiographies [29]. Robotic-assisted CAB has also shown a benefit in hospital length of stay, return to full activity, and pain scores when compared to conventional CABG. More recently, Currie et al reported long-term follow-up of 82 patients who underwent robotic-assisted CAB with a 93.4% patency rate at a mean follow-up of 96 months [30]. This study also demonstrated a positive effect on the patients' quality of life, however, there was no comparison to standard CABG.

Data from the few centers that have adopted TECAB has been favorable as well. In 2006 a multicenter trial of 98 patients reported a low rate of conversion to sternotomy (6%), a low MACCE rate, and freedom from reintervention or angiographic failure of 91% [31]. Since that time, high volume TECAB centers have consistently shown good clinical results, however angiographic follow-up has been limited [32]. Few authors have called into question the safety of single vessel TECAB, however, some have argued that multivessel TECAB may be deleterious when compared to conventional surgery [33].

High-level evidence for HCR is still lacking, with no randomized trials available in the literature and all results to date coming from single-institution reports. Furthermore, data extending to 10-years for PCI with DES is unavailable, and given that SVGs likely offer some protection from "future lesions", it is unclear how outcomes with DES will compare to SVGs. However, the data that is currently available has shown HCR to be safe and effective. Since the earliest reports were published in 1996, studies have consistently described low mortality, a low incidence of conversion to sternotomy, and excellent graft patency with an acceptable incidence of repeat revascularization in non-LAD territories [34-43]. Shen et al. recently published a series of 141 patients who underwent concomitant HCR via a partial lower sternotomy [44]. These patients were propensity matched with groups of patients having undergone CABG alone or PCI alone. MACCE rate was 6.4% in the HCR group, which was numerically lower than with CABG (13.4%) and significantly lower than PCI (22.7%, $p=0.003$ compared to HCR). Other studies have shown advantages with HCR over CABG in reference to ICU and hospital length of stay, intubation time, perioperative blood loss, transfusion requirements, and patient satisfaction [45,46]. While short-term data would suggest outcomes with HCR that are comparable to CABG, long-term results are limited. In 2011 we published a report comparing results in 147 patients treated with HCR matched to 588 patients treated with multivessel OPCAB [47]. Transfusion rates were higher with the OPCAB group, while the incidence of MACCE was similar between the 2 groups. Not surprisingly, at median follow-up of 3.2 years, repeat revascularization was higher with HCR (12.2% vs. 3.7%, $p<0.001$), however, the vast majority were in the vessels treated percutaneously and there was no difference in estimated 5-year survival

84.3% vs. 86.8%). A recent report suggested that patients with higher SYNTAX scores that are greater risk perioperative of mortality may have better 30-day outcomes with traditional CABG [48]. When we evaluated a subset of patients with left main coronary artery stenosis, we found a higher incidence of repeat revascularization with HCR that was not statistically significant [16]. Another large series, reported by Hu et al., compared the results of simultaneous hybrid revascularization with OPCAB and showed superb results in both groups with no need for revascularization at 18 months [49].

Several authors have demonstrated that despite higher initial costs with HCR, particularly if robotic technology is used, savings in postoperative expenses result in favorable cost effectiveness analysis compared to OPCAB [38,46,50]. Initial costs of purchasing the robotic telemanipulation systems are often not included in these reports and would obviously impact overall costs; however these expenses are spread over several surgical services. These studies have also showed an earlier return to work with HCR, which results in less absenteeism and societal cost savings.

Conclusion

When compared to traditional CABG, HCR may be advantageous with regard to ICU and hospital LOS as well as lower transfusion requirements. These benefits likely come at the cost of an increased incidence of repeat revascularization and higher initial costs, however, the short- and mid-term data available to date are very encouraging, with excellent in-hospital outcomes and no evidence of compromised survival compared to traditional CABG. HCR has proven to be a viable alternative to both multivessel PCI and traditional CABG that affords complete revascularization for patients with multivessel CAD. We believe that robotic assisted surgery will play an important role in the future of HCR by providing the surgeon with the heightened visualization and dexterity to operate in small spaces. This technology will no doubt continue to evolve and overcome some of its current limitations, becoming even safer and more exploitable by appropriately trained or proctored cardiac surgeons. In an era where patients and cardiologists seek the least invasive treatment option with variable consideration for long-term results, HCR offers the durability and survival benefit of LIMA-LAD bypass and the symptom relief PCI in a minimally invasive bundle. While initial reports comparing HCR to CABG have been favorable, larger well-designed trials with long-term follow-up are necessary to solidify the role of this approach in the treatment of patients with multivessel coronary artery disease.

References

1. TIME Investigators (2001) Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease (TIME): a randomised trial. *Lancet* 358: 951-957.
2. Bucher HC, Hengstler P, Schindler C, Guyatt GH (2000) Percutaneous transluminal coronary angioplasty versus medical treatment for non-acute coronary heart disease: meta-analysis of randomised controlled trials. *BMJ* 321: 73-77.
3. Hueb W, Lopes N, Gersh BJ, Soares PR, Ribeiro EE, et al. (2010) Ten-year follow-up survival of the Medicine, Angioplasty, or Surgery Study (MASS II): a randomized controlled clinical trial of 3 therapeutic strategies for multivessel coronary artery disease. *Circulation* 122: 949-957.
4. Loop FD, Lytle BW, Cosgrove DM, Stewart RW, Goormastic M, et al. (1986) Influence of the internal-mammary-artery graft on 10-year survival and other cardiac events. *N Engl J Med* 314: 1-6.
5. Tatoulis J, Buxton BF, Fuller JA (2004) Patencies of 2127 arterial to coronary conduits over 15 years. *Ann Thorac Surg* 77: 93-101.
6. Goldman S, Zadina K, Moritz T, Ovitt T, Sethi G, et al. (2004) Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery: results from a Department of Veterans Affairs Cooperative Study. *J Am Coll Cardiol* 44: 2149-2156.
7. Mohr FW, Morice MC, Kappetein AP, Feldman TE, Stähle E, et al. (2013) Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. *Lancet* 381: 629-638.
8. Ashby DT, Dangas G, Mehran R, Lansky AJ, Narasimaiah R, et al. (2002) Comparison of clinical outcomes using stents versus no stents after percutaneous coronary intervention for proximal left anterior descending versus proximal right and left circumflex coronary arteries. *Am J Cardiol* 89: 1162-1166.
9. Weisz G, Leon MB, Holmes DR Jr, Kereiakes DJ, Clark MR, et al. (2006) Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial. *J Am Coll Cardiol* 47: 1350-1355.
10. Calafiore AM, Giammarco GD, Teodori G, Bosco G, D'Annunzio E, et al. (1996) Left anterior descending coronary artery grafting via left anterior small thoracotomy without cardiopulmonary bypass. *Ann Thorac Surg* 61: 1658-1663.
11. Subramanian VA, McCabe JC, Geller CM (1997) Minimally invasive direct coronary artery bypass grafting: two-year clinical experience. *Ann Thorac Surg* 64: 1648-1653.
12. Buceri J, Metz S, Walther T, Falk V, Doll N, et al. (2002) Endoscopic internal thoracic artery dissection leads to significant reduction of pain after minimally invasive direct coronary artery bypass graft surgery. *Ann Thorac Surg* 73: 1180-1184.
13. Trehan N, Malhotra R, Mishra Y, Shrivastava S, Kohli V, et al. (2000) Comparison of ministernotomy with minithoracotomy regarding postoperative pain and internal mammary artery characteristics. *Heart Surg Forum* 3: 300-306.
14. Thiele H, Neumann-Schriedewind P, Jacobs S, Boudriot E, Walther T, et al. (2009) Randomized Comparison of Minimally Invasive Direct Coronary Artery Bypass Surgery Versus Sirolimus-Eluting Stenting in Isolated Proximal Left Anterior Descending Coronary Artery Stenosis. *J Am Coll Cardiol* 53: 2324-2331.
15. Acharya MN, Ashrafian H, Athanasios T, Casula R (2012) Is totally endoscopic coronary artery bypass safe, feasible and effective? *Interact Cardiovasc Thorac Surg* 15: 1040-1046.
16. Halkos ME, Rab ST, Vassiliades TA, Morris DC, Douglas JS, et al. (2011) Hybrid coronary revascularization versus off-pump coronary artery bypass for the treatment of left main coronary stenosis. *Ann Thorac Surg* 92: 2155-2160.
17. Halkos ME, Vassiliades TA, Myung RJ, Kilgo P, Thourani VH, et al. (2012) Sternotomy versus nonsternotomy LIMA-LAD grafting for single-vessel disease. *Ann Thorac Surg* 94: 1469-1477.
18. Srivastava MC, Vesely MR, Lee JD, Lehr EJ, Wehman B, et al. (2013) Robotically assisted hybrid coronary revascularization: does sequence of intervention matter? *Innovations (Phila)* 8: 177-183.
19. Mack MJ, Magovern JA, Acuff TA, Landreneau RJ, Tennison DM, et al. (1999) Results of graft patency by immediate angiography in minimally invasive coronary artery surgery. *Ann Thorac Surg* 68: 383-389.
20. Holzhey DM, Jacobs S, Mochalski M, Walther T, Thiele H, et al. (2007) Seven-year follow-up after minimally invasive direct coronary artery bypass: experience with more than 1300 patients. *Ann Thorac Surg* 83: 108-114.
21. Fraund S, Herrmann G, Witzke A, Hedderich J, Lutter G, et al. (2005) Midterm follow-up after minimally invasive direct coronary artery bypass grafting versus percutaneous coronary intervention techniques. *Ann Thorac Surg* 79: 1225-1231.
22. Mehran R, Dangas G, Stamou SC, Pfister AJ, Dullum MK, et al. (2000) One-year clinical outcome after minimally invasive direct coronary artery bypass. *Circulation* 102: 2799-2802.
23. Diegeler A, Walther T, Metz S, Falk V, Krakor R, et al. (1999) Comparison of MIDCAP versus conventional CABG surgery regarding pain and quality of life. *Heart Surg Forum* 2: 290-295.
24. Al-Ruzzeh S, Mazrani W, Wray J, Modine T, Nakamura K, et al. (2004) The clinical outcome and quality of life following minimally invasive direct coronary artery bypass surgery. *J Card Surg* 19: 12-16.
25. Ben-Gal Y, Mohr R, Braunstein R, Finkelstein A, Hansson N, et al. (2006) Revascularization of left anterior descending artery with drug-eluting stents: comparison with minimally invasive direct coronary artery bypass surgery. *Ann Thorac Surg* 82: 2067-2071.

26. Jaffery Z, Kowalski M, Weaver WD, Khanal S (2007) A meta-analysis of randomized control trials comparing minimally invasive direct coronary bypass grafting versus percutaneous coronary intervention for stenosis of the proximal left anterior descending artery. *Eur J Cardiothorac Surg* 31: 691–697.
27. Vassiliades TA Jr, Reddy VS, Puskas JD, Guyton RA (2007) Long-term results of the endoscopic atraumatic coronary artery bypass. *Ann Thorac Surg* 83: 979-984.
28. Daniel WT, Puskas JD, Baio KT, Liberman HA, Devireddy C, et al. (2012) Lessons learned from robotic-assisted coronary artery bypass surgery: risk factors for conversion to median sternotomy. *Innovations (Phila)* 7: 323-327.
29. Nesher N, Bakir I, Casselman F, Degrieck I, De Geest R, et al. (2007) Robotically enhanced minimally invasive direct coronary artery bypass surgery: a winning strategy? *J Cardiovasc Surg (Torino)* 48: 333-338.
30. Currie ME, Romsa J, Fox SA, Vezina WC, Akincioglu C, et al. (2012) Long-term angiographic follow-up of robotic-assisted coronary artery revascularization. *Ann Thorac Surg* 93: 1426-1431.
31. Argenziano M, Katz M, Bonatti J, Srivastava S, Murphy D, et al. (2006) Results of the prospective multicenter trial of robotically assisted totally endoscopic coronary artery bypass grafting. *Ann Thorac Surg* 81: 1666-1674.
32. Bonaros N, Schachner T, Lehr E, Kofler M, Wiedemann D, et al. (2013) Five hundred cases of robotic totally endoscopic coronary artery bypass grafting: predictors of success and safety. *Ann Thorac Surg* 95: 803-812.
33. Dhawan R, Roberts JD, Wroblewski K, Katz JA, Raman J, et al. (2012) Multivessel beating heart robotic myocardial revascularization increases morbidity and mortality. *J Thorac Cardiovasc Surg* 143: 1056-1061.
34. Angelini GD, Wilde P, Salerno TA, Bosco G, Calafiore AM (1996) Integrated left small thoracotomy and angioplasty for multivessel coronary artery revascularisation. *Lancet* 347: 757-758.
35. Cohen HA, Zenati M, Smith AJ, Lee JS, Chough S, et al. (1998) Feasibility of combined percutaneous transluminal angioplasty and minimally invasive direct coronary artery bypass in patients with multivessel coronary artery disease. *Circulation* 98: 1048–1050.
36. Lloyd CT, Calafiore AM, Wilde P, Ascione R, Paloscia L, et al. (1999) Integrated left anterior small thoracotomy and angioplasty for coronary artery revascularization. *Ann Thorac Surg* 68: 908-911.
37. Isomura T, Suma H, Horii T, Sato T, Kobashi T, et al. (2000) Minimally invasive coronary artery revascularization: off-pump bypass grafting and the hybrid procedure. *Ann Thorac Surg* 70: 2017-2022.
38. de Cannière D, Jansens JL, Goldschmidt-Clermont P, Barvais L, Decroly P, et al. (2001) Combination of minimally invasive coronary bypass and percutaneous transluminal coronary angioplasty in the treatment of double-vessel coronary disease: Two-year follow-up of a new hybrid procedure compared with “on-pump” double bypass grafting. *Am Heart J* 142: 563–570.
39. Cisowski M, Morawski W, Drzewiecki J, Kruczek W, Toczek K, et al. (2002) Integrated minimally invasive direct coronary artery bypass grafting and angioplasty for coronary artery revascularization. *Eur J Cardiothorac Surg* 22: 261-265.
40. Davidavicius G, Van Praet F, Mansour S, Casselman F, Bartunek J, et al. (2005) Hybrid revascularization strategy: a pilot study on the association of robotically enhanced minimally invasive direct coronary artery bypass surgery and fractional-flow-reserve-guided percutaneous coronary intervention. *Circulation* 112: 1317–1322.
41. Kiaii B, McClure RS, Stewart P, Rayman R, Swinamer SA, et al. (2008) Simultaneous integrated coronary artery revascularization with long-term angiographic follow-up. *J Thorac Cardiovasc Surg* 136: 702-708.
42. Gao C, Yang M, Wu Y, Wang G, Xiao C, et al. (2009) Hybrid coronary revascularization by endoscopic robotic coronary artery bypass grafting on beating heart and stent placement. *Ann Thorac Surg* 87: 737-741.
43. Vassiliades TA Jr, Douglas JS, Morris DC, Block PC, Ghazzal Z, et al. (2006) Integrated coronary revascularization with drug-eluting stents: immediate and seven-month outcome. *J Thorac Cardiovasc Surg* 131: 956-962.
44. Shen L, Hu S, Wang H, Xiong H, Zheng Z, et al. (2013) One-stop hybrid coronary revascularization versus coronary artery bypass grafting and percutaneous coronary intervention for the treatment of multivessel coronary artery disease: 3-year follow-up results from a single institution. *J Am Coll Cardiol* 61: 2525-2533.
45. Reicher B, Poston RS, Mehra MR, Joshi A, Odonkor P, et al. (2008) Simultaneous “hybrid” percutaneous coronary intervention and minimally invasive surgical bypass grafting: feasibility, safety, and clinical outcomes. *Am Heart J* 155: 661–667.
46. Kon ZN, Brown EN, Tran R, Joshi A, Reicher B, et al. (2008) Simultaneous hybrid coronary revascularization reduces postoperative morbidity compared with results from conventional off-pump coronary artery bypass. *J Thorac Cardiovasc Surg* 135: 367-375.
47. Halkos ME, Vassiliades TA, Douglas JS, Morris DC, Rab ST, et al. (2011) Hybrid coronary revascularization versus off-pump coronary artery bypass grafting for the treatment of multivessel coronary artery disease. *Ann Thorac Surg* 92: 1695-1701.
48. Leacche M, Byrne JG, Solenkova NS, Reagan B, Mohamed TI, et al. (2013) Comparison of 30-day outcomes of coronary artery bypass grafting surgery versus hybrid coronary revascularization stratified by SYNTAX and euroSCORE. *J Thorac Cardiovasc Surg* 145: 1004-1012.
49. Hu S, Li Q, Gao P, Xiong H, Zheng Z, et al. (2011) Simultaneous hybrid revascularization versus off-pump coronary artery bypass for multivessel coronary artery disease. *Ann Thorac Surg* 91: 432-438.
50. Poston RS, Tran R, Collins M, Reynolds M, Connerney I, et al. (2008) Comparison of Economic and Patient Outcomes With Minimally Invasive Versus Traditional Off-Pump Coronary Artery Bypass Grafting Techniques. *Transactions of the Meeting of the American Surgical Association* 126: 281–289.

Citation: Moss E, Puskas JD, Halkos ME (2013) Hybrid Coronary Revascularization for Multivessel Coronary Artery Disease: Strategies and Outcomes. *J Clin Exp Cardiol* S7: 006. doi: [10.4172/2155-9880.S7-006](https://doi.org/10.4172/2155-9880.S7-006)

This article was originally published in a special issue, [Advances in Cardiac Surgery and Therapeutics](#) handled by Editor(s). Dr. Wilbert S. Aronow, New York Medical College, USA

Submit your next manuscript and get advantages of OMICS Group submissions

Unique features:

- User friendly/feasible website-translation of your paper to 50 world's leading languages
- Audio Version of published paper
- Digital articles to share and explore

Special features:

- 250 Open Access Journals
- 20,000 editorial team
- 21 days rapid review process
- Quality and quick editorial, review and publication processing
- Indexing at PubMed (partial), Scopus, EBSCO, Index Copernicus and Google Scholar etc
- Sharing Option: Social Networking Enabled
- Authors, Reviewers and Editors rewarded with online Scientific Credits
- Better discount for your subsequent articles

Submit your manuscript at: www.editorialmanager.com/clinicalgroup

